VKTX Stock Recent News

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Weight loss medications are fueling the pharmaceutical industry right now. One potential side effect of losing weight can be reductions in muscle mass -- which can pose serious health issues.

Viking aims to challenge big pharma players Eli Lilly and Novo Nordisk in the multibillion-dollar weight loss drug market. It recently reported excellent clinical trial results for its injectable and oral tablet weight loss candidates.

Upstart biotech Viking Therapeutics is hoping to enter the weight loss treatment market. The company has released encouraging data from clinical trials for its candidate, VK2735.

Viking Therapeutics is testing an oral version of its leading candidate. The biotech recently reported positive phase 1 results for this formulation.

There's an ongoing gold rush for medicines that treat obesity. Viking Therapeutics already has two strong contenders in clinical trials.

Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.

GLP-1 (Semaglutide) drugs like Ozempic and Wegovy produced by Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound (Tirzepatide) produced by Eli Lilly and Co. NYSE: LLY have taken the mainstream by storm. These drugs have transformed the medical sector.